title: Prevention and treatment of cancer-related infections.
abstract: Patients with cancer are at increased risk for developing infectious complications during the course of their disease and treatment. The following sections of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections provide an overview of the risk factors for infectious complications, recommendations for infectious risk categorization, and strategies for prevention of infections in high-risk patient populations with cancer. Individualized risk evaluation for infections and incorporation of preventative measures are essential components of the overall spectrum of cancer care, and may contribute to optimizing treatment outcomes for patients.
authors.forename: Lindsey Robert
authors.initials: LR
authors.lastname: Baden
authors.forename: William
authors.initials: W
authors.lastname: Bensinger
authors.forename: Michael
authors.initials: M
authors.lastname: Angarone
authors.forename: Corey
authors.initials: C
authors.lastname: Casper
authors.forename: Erik R
authors.initials: ER
authors.lastname: Dubberke
authors.forename: Alison G
authors.initials: AG
authors.lastname: Freifeld
authors.forename: Ramiro
authors.initials: R
authors.lastname: Garzon
authors.forename: John N
authors.initials: JN
authors.lastname: Greene
authors.forename: John P
authors.initials: JP
authors.lastname: Greer
authors.forename: James I
authors.initials: JI
authors.lastname: Ito
authors.forename: Judith E
authors.initials: JE
authors.lastname: Karp
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Kaul
authors.forename: Earl
authors.initials: E
authors.lastname: King
authors.forename: Emily
authors.initials: E
authors.lastname: Mackler
authors.forename: Kieren A
authors.initials: KA
authors.lastname: Marr
authors.forename: Jose G
authors.initials: JG
authors.lastname: Montoya
authors.forename: Ashley
authors.initials: A
authors.lastname: Morris-Engemann
authors.forename: Peter G
authors.initials: PG
authors.lastname: Pappas
authors.forename: Ken
authors.initials: K
authors.lastname: Rolston
authors.forename: Brahm
authors.initials: B
authors.lastname: Segal
authors.forename: Susan K
authors.initials: SK
authors.lastname: Seo
authors.forename: Sankar
authors.initials: S
authors.lastname: Swaminathan
authors.forename: Maoko
authors.initials: M
authors.lastname: Naganuma
authors.forename: Dorothy A
authors.initials: DA
authors.lastname: Shead
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000209:etiology / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D009181:Mycoses / Q000209:etiology / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D012307:Risk Factors; D014777:Virus Diseases / Q000209:etiology / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D000998:Antiviral Agents